Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) and Arcus Biosciences (NYSE:RCUS – Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations.
Institutional & Insider Ownership
47.5% of Dianthus Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 3.0% of Dianthus Therapeutics shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Dianthus Therapeutics and Arcus Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dianthus Therapeutics | -10,096.95% | -22.53% | -21.55% |
| Arcus Biosciences | -393.16% | -89.54% | -45.61% |
Earnings and Valuation
This table compares Dianthus Therapeutics and Arcus Biosciences”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dianthus Therapeutics | $2.04 million | 2,109.53 | -$162.34 million | ($4.15) | -18.92 |
| Arcus Biosciences | $247.00 million | 10.04 | -$353.00 million | ($3.90) | -4.99 |
Dianthus Therapeutics has higher earnings, but lower revenue than Arcus Biosciences. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Dianthus Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Dianthus Therapeutics and Arcus Biosciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dianthus Therapeutics | 1 | 0 | 13 | 1 | 2.93 |
| Arcus Biosciences | 1 | 3 | 12 | 0 | 2.69 |
Dianthus Therapeutics presently has a consensus price target of $129.83, indicating a potential upside of 65.33%. Arcus Biosciences has a consensus price target of $39.64, indicating a potential upside of 103.57%. Given Arcus Biosciences’ higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than Dianthus Therapeutics.
Summary
Dianthus Therapeutics beats Arcus Biosciences on 8 of the 15 factors compared between the two stocks.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
